Immunovant, Inc. · NASDAQ:IMVT
Immunovant — Corporate Update (November 2023)
27 slides from Immunovant's corporate update, Nov 28, 2023
Slide 1: Targeted science, Tailored solutions
Targeted science, Tailored solutions for people with autoimmune disease Portfolio Update November 28, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “ex
Slide 3: Our Vision: Normal Lives for People with Autoimmune Disease
Our Vision: Normal Lives for People with Autoimmune Disease What we do: We are developing targeted therapies that are designed to address the complex and variable needs of people with autoimmune diseases. Love Bolder, All Trailblazing Faster Voices 3
Slide 4: Goals for the Phase 1 Program
Goals for the Phase 1 Program Demonstrate potential best-in-class IgG reductions similar to batoclimab Demonstrate minimal to no impact on albumin Demonstrate minimal to no impact on LDL Achieve all of the above with a simple, commercially attractive subcutaneous injection Note: Based on data to dat
Slide 5: Best-in-Class Potential for IMVT-1402 – Why it Matters
Best-in-Class Potential for IMVT-1402 – Why it Matters FcRn inhibition is a proven mechanism with broad potential applicability based on targeted reduction of IgG as an improved and more targeted modality Evidence across broad range of auto-antibody conditions that deeper IgG reduction correlates wi
Slide 6: Multiple-Ascending Subcutaneous Doses
Multiple-Ascending Subcutaneous Doses (Once-weekly dosing x 4 weeks)
Slide 7: IMVT-1402 600mg MAD Data Consistent with 300mg MAD Data
IMVT-1402 600mg MAD Data Consistent with 300mg MAD Data IgG % change over time Albumin % change over time LDL % change over time IMVT-1402: Multiple-ascending SC Dose IMVT-1402: Multiple-ascending SC Dose IMVT-1402: Multiple-ascending SC Dose 40% 20% 50% 40% 20% 10% 30% 0% 20% 0% -20% 10% -10% 0% -4
Slide 8: IMVT-1402 MAD Data Suggests Potential Best-in-Class IgG Reduction
IMVT-1402 MAD Data Suggests Potential Best-in-Class IgG Reduction IgG % change over time IMVT-1402: Multiple-ascending 600mg SC Dose IMVT-1402: Multiple-ascending 300mg SC Dose 40% 40% 20% 20% 0% 0% -20% -20% -40% -40% -60% -60% -80% -80% -100% -100% ng ng 0 5 0 5 10 15 20 25 30 10 15 20 25 30 ni ni
Slide 9: IMVT-1402 MAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab
IMVT-1402 MAD Data Suggests Potential Best-in-Class IgG Reduction Similar to Batoclimab* IgG % change over time Multiple-ascending SC Dose 40% 20% 0% -20% -40% -60% -80% -100% 0 5 10 15 20 25 30 IMVT-1402: MAD SC 600mg Group Mean Day IMVT-1402: MAD SC 300mg Group Mean IMVT-1402: MAD SC Placebo (600m
Slide 10: IMVT-1402 MAD Data: Minimal to No Albumin Reduction
IMVT-1402 MAD Data: Minimal to No Albumin Reduction, Similar to Placebo, After Four Weeks of Dosing Albumin % change over time IMVT-1402: Multiple-ascending 600mg SC Dose IMVT-1402: Multiple-ascending 300mg SC Dose 20% 20% 10% 10% 0% 0% -10% -10% -20% -20% -30% -30% -40% -40% ng ng 0 5 0 5 10 15 20
Slide 11: IMVT-1402 MAD Data: Minimal to No LDL Increase
IMVT-1402 MAD Data: Minimal to No LDL Increase, Similar to Placebo, After Four Weeks of Dosing LDL % change over time IMVT-1402: Multiple-ascending 600mg SC Dose IMVT-1402: Multiple-ascending 300mg SC Dose 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% -10% -10% -20% -20% -30% -30% -40% -40% -50% -50
Slide 12: IMVT-1402 Showed a Favorable Safety Profile in Initial Phase 1 Data Set
IMVT-1402 Showed a Favorable Safety Profile in Initial Phase 1 Data Set SC SAD SC MAD Placebo 300mg 600mg Placebo 300mg 600mg N=4 N=6 N=6 N=4 N = 10 N = 10 n (%) n (%) n (%) n (%) n (%) n (%) Participants with at least one TEAE 3 (75) 4 (67) 5 (83) 4 (100) 7 (70) 6 (60) Participants with at least on
Slide 13: IgG Reduction and Clinical Efficacy Correlation
IgG Reduction and Clinical Efficacy Correlation
Slide 14: Best-in-Class Potential for IMVT-1402 – Why it Matters
Best-in-Class Potential for IMVT-1402 – Why it Matters FcRn inhibition is a proven mechanism with broad potential applicability based on targeted reduction of IgG as an improved and more targeted modality Evidence across broad range of auto-antibody conditions that deeper IgG reduction correlates wi
Slide 15: Consistent Evidence Across Programs that Greater IgG Reduction Leads to Greater Efficacy
Consistent Evidence Across Programs and Indications that Greater IgG Reduction Leads to Greater Efficacy* Company Evidence of Greater IgG Reductions Translating to Clinical Benefit Patient-level scatter plot showed that greater IgG declines è greater MG MG-ADL improvements Greater IgG reduction acro
Slide 16: Efgartigimod MG and PV Data Showed Higher Clinical Response with Deeper IgG Reduction
Efgartigimod MG and PV Data Showed Higher Clinical Response with Deeper IgG Reduction ADAPT Phase 3 trial of IV efgartigimod in MG showed a In efgartigimod Phase 2 in PV, more intensive dosing regimens correlation between IgG reductions and clinical response led to deeper skin responses Dosing Cohor
Slide 17: Nipocalimab MG and RA Data Showed Higher Clinical Response with Deeper IgG Reduction
Nipocalimab MG and RA Data Showed Higher Clinical Response with Deeper IgG Reduction Nipocalimab Phase 2 trial in MG showed a Nipocalimab Phase 2 trial in RA showed a correlation correlation between IgG reductions and clinical between auto-Ab reductions and clinical response response Source: Momenta
Slide 18: Batoclimab TED Data Showed Higher Clinical Response with Deeper IgG Reduction
Batoclimab TED Data Showed Higher Clinical Response with Deeper IgG Reduction Deeper IgG reduction led to greater restoration of normal levels of pathogenic antibodies and greater proptosis response in Phase 2 trial in TED Batoclimab Batoclimab Batoclimab Placebo 255 mg 340 mg 680 mg Median Max % Ig
Slide 19: Rozanolixizumab ITP Data Showed Higher Clinical Response with Deeper IgG Reduction
Rozanolixizumab ITP Data Showed Higher Clinical Response with Deeper IgG Reduction In UCB’s Phase 2 trial in ITP, higher doses and greater IgG reductions were associated with better platelet responses Data at Day 8 Single Dose of Rozanolixizumab Estimated IgG Mean platelet count % change platelet Re
Slide 20: Portfolio Development for IMVT-1402
Portfolio Development for IMVT-1402
Slide 21: Best-in-Class Potential for IMVT-1402 – Why it Matters
Best-in-Class Potential for IMVT-1402 – Why it Matters FcRn inhibition is a proven mechanism with broad potential applicability based on targeted reduction of IgG as an improved and more targeted modality Evidence across broad range of auto-antibody conditions that deeper IgG reduction correlates wi
Slide 22: Creating the Best Portfolio of Indications for IMVT-1402
Creating the Best Portfolio of Indications for IMVT-1402 Guided by IgG biomarker in proven mechanism with well-characterized safety profile Addressable population Unmet patient need Potential to address Competitive differentiation multiple indications in an exciting class Technical success probabili
Slide 23: Potential Best-in-Class Product Profile Opens Broad Range of Indication Opportunities
Potential Best-in-Class Product Profile Opens Broad Range of Indication Opportunities for IMVT-1402 • Assuming differentiated benefit/risk and simple SC delivery, High unmet opportunity to leverage potency of 1402 to further expand First-in-Class applicable patient types for anti-FcRn development ne
Slide 24: Examples of Potential First-in-Class and/or Best-in-Class Indications
Examples of Potential First-in-Class and/or Best-in-Class Indications* Graves’ Disease Rheumatoid Arthritis Large unmet need between oral anti-thyroid Large unmet need in refractory rheumatoid arthritis 1 medications (ATD) that work for many & definitive 1 (RA) for patients who fail to respond to mo
Slide 25: Concluding Thoughts
Concluding Thoughts \f IMMUNOVANT
Slide 26: IMVT-1402 Has Potentially Best-In-Class Attributes to Address Large Unmet Need
IMVT-1402 Has Potentially Best-In-Class Attributes to Address Large Unmet Need in Autoimmune Disease IMVT-1402 + + Deep IgG Lowering Initial Phase 1 data suggests deep + dose-dependent IgG lowering similar to batoclimab Favorable Analyte Profile Initial Phase 1 data supports a favorable analyte prof
Slide 27: Concluding Thoughts
Concluding Thoughts IMIVT-1402’s 2024 will be a big The proven anti- profile and year for IMVT-1402 FcRn class keeps potency creates an as we announce a getting more exciting range of broad portfolio of exciting potential pivotal trials and indications POCs 27